Lung Cancer in India

Singh, Navneet; Agrawal, Sushma; Jiwnani, Sabita; Khosla, Divya; Malik, Prabhat Singh; Mohan, Anant; Penumadu, Prasanth; Prasad, Kuruswamy Thurai

doi:10.1016/j.jtho.2021.02.004

Cited by 59 publications

(29 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In India, the prevalence of the two commonest oncogenic driver alterations, namely, EGFR mutations[ 2 , 84 – 86 ] is approximately 25.3%–30% and of ALK rearrangements[ 2 , 85 ] is approximately 10%–11.5%, and 33.6% have PD-L1 expression. [ 87 ] The national guidelines also recommend testing for EGFR , ALK , ROS1 rearrangements, and PD-L1 overexpression for all patients with NSCLC in the frontline to provide improved treatment opportunities, including targeted therapy.…”

Section: Role Of Biomarkers In Early Diagnosis Of Lung Cancermentioning

confidence: 99%

“…Notably, because of the high prevalence of EGFR mutations and ALK/ROS1 rearrangements and gradually improving access to novel TKIs in the country at considerably lower costs, the Indian Council of Medical Research (ICMR) has launched a nationwide Advanced Molecular Oncology Diagnostic Services project to provide biomarker testing for LC free of cost throughout the country. [ 85 ]…”

Section: Screening For Lung Cancer In India and Policy Considerationmentioning

confidence: 99%

See 1 more Smart Citation

Navigating patient journey in early diagnosis of lung cancer in India

Biswas

Talwar²,

Meshram³

et al. 2023

Lung India

View full text Add to dashboard Cite

Lung cancer (LC) is one of the leading causes of cancer deaths worldwide. In India, the incidence of LC is increasing rapidly, and a majority of the patients are diagnosed at advanced stages of the disease when treatment is less likely to be effective. Recent therapeutic developments have significantly improved survival outcomes in patients with LC. Prompt specialist referral remains critical for early diagnosis for improved patient survival. In the Indian scenario, distinguishing LC from benign and endemic medical conditions such as tuberculosis can pose a challenge. Hence, awareness regarding the red flags—signs and symptoms that warrant further investigations and referral—is vital. This review is an effort toward encouraging general physicians to maintain a high index of clinical suspicion for those at risk of developing LC and assisting them in refering patients with concerning symptoms to specialists or multidisciplinary teams as early as possible.

show abstract

Section: Role Of Biomarkers In Early Diagnosis Of Lung Cancermentioning

confidence: 99%

Section: Screening For Lung Cancer In India and Policy Considerationmentioning

confidence: 99%

Navigating patient journey in early diagnosis of lung cancer in India

Biswas

Talwar²,

Meshram³

et al. 2023

Lung India

View full text Add to dashboard Cite

show abstract

“…For example, India has radiotherapy equipment to serve only half of its current population. 28 Furthermore, only bigger cities within each country have established radiotherapy centers, making it difficult for the rural population to use them. Additionally, patients have a high wait time to receive RT due to limited availability.…”

Section: Management Of Non-metastatic Lung Cancermentioning

confidence: 99%

Lung cancer management in low and middle-income countries - current challenges and potential solutions

Uprety

Surapaneni

2023

International Journal of Cancer Care and Delivery

View full text Add to dashboard Cite

Lung cancer is the second-most prevalent cancer and, the most common cause of cancer-related mortality throughout the world. Evidence-based strategies to decrease its incidence and mortality are being implemented in different parts of the world. Smoking cessation policies are being actively publicized to decrease the incidence of tobacco related cancers including lung cancer. Screening program for early detection of localized lung cancer which can then be targeted by a multimodality approach utilizing surgery, radiation, chemoimmunotherapy to achieve cure is now becoming the standard in several high-income countries. Precision medicine in lung cancer is booming with metastatic non-curative cancers targeted with small molecule tyrosine kinase inhibitors. However, these advancements are not available all around the world. Inequalities exist in the management of lung cancer, mostly driven by the economic differences between the countries. Raising awareness to these international barriers is pivotal for improving lung cancer related incidence and mortality.

show abstract

“…But this past decade has seen a shift in the incidence from tobacco dependent lung cancer to tobacco-independent lung cancers, making adenocarcinoma the dominant histologic type. 6 This shift could be a result of the decrease in prevalence of tobacco use by about 81 lakhs from global adult tobacco survey-1 (2009-10) to global adult tobacco survey-2 (2016-17) in India, and improvements in histologic typing subtype analysis for molecular mutations such as epidermal growth factor receptor (EGFR), BRAF, MET, ERBB2, & fusion markers such as anaplastic lymphoma kinase (ALK), ROS-1, RET, NTRK rearrangements. 7 The rising number of accredited facilities for gene sequencing have considerably made the testing faster, cheaper, and more frequent leading to an increasing need for newer modalities that provide specific treatment.…”

mentioning

confidence: 99%

“…ICMR has also launched a national DHR-ICMR advanced molecular oncology diagnostic services project to provide for free of cost biomarker testing of lung cancer throughout India. 6 All these factors have led to an increase in the randomised control trials being conducted for non-small cell lung cancer. Hence, we aimed to analyse those registered on clinical trial registry of India.…”

mentioning

confidence: 99%

An analysis of studies on non-small cell lung cancer registered on clinical trials registry of India

Marolia

Nerurkar

Vazifdar

2022

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Lung cancer is the most common cancer in males, of which non-small cell type is more prevalent. It is an active area of research owing to the limited available treatment modalities with several studies registered on CTRI. Objectives of current study was to analyse randomized control trials for non-small cell lung cancer registered on clinical trial registry India.Methods: Studies registered on CTRI were reviewed in this registry-based audit using the keywords lung cancer and non-small cell lung cancer. Parameters such as type of study, nature of intervention, phase of study, primary and secondary endpoints used, etc, were analysed and summarised using descriptive statistics in Microsoft Excel 365.Results: Out of 230 trials for lung cancer, 121 studied non-small cell lung cancer, of which 103 studies (85.1%) were interventional studies. Most common intervention under study was drug 97 studies (94.2%) followed by radiation 4 studies (3.3%). Majority of trials were phase 3, 48 trials (39.7%) and only 4 (3.3%) studies were phase 1. Five most common primary and secondary endpoints observed were survival, response rate, safety, pharmacokinetic data & quality of life. Maximum patients were in the advanced stage of cancer(52.1%) and pemetrexed (9.9%) was the most common drug used.Conclusions: We observed an increasing trend in studies registered on CTRI, with maximum studies in phase 3 with patients in the advanced stage of cancer having overall survival as the endpoint.

show abstract

Lung Cancer in India

Cited by 59 publications

References 34 publications

Navigating patient journey in early diagnosis of lung cancer in India

Navigating patient journey in early diagnosis of lung cancer in India

Lung cancer management in low and middle-income countries - current challenges and potential solutions

An analysis of studies on non-small cell lung cancer registered on clinical trials registry of India

Contact Info

Product

Resources

About